Area of research
Oncology · Physiology
Research interest
Research interests include Adenosine and Purinergic Signaling, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, and Peptidase Inhibition and Analysis.
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.
The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.
Supplementary Data from Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis
Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial
Data from Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis
Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Supplementary Data from Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis
CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma
The CD73 immune checkpoint promotes tumor cell metabolic fitness.
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties.
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conference.
Author response: The CD73 immune checkpoint promotes tumor cell metabolic fitness
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Supplementary Data from IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma
Supplementary Tables and Figures from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Data from IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma
Supplementary Data from IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma
Predicting developmental relationships of tumor resident and circulating T cells in ovarian cancer
Data from IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma
Data from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Data from CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
Spatially mapping the immune landscape of melanoma using imaging mass cytometry.